Liminatus Pharma, Inc. Class A Common Stock (LIMN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 3.47 |
| Open | 3.45 |
| Day High | 3.66 |
| Day Low | 3.29 |
| 52-Week High | 141.5 |
| 52-Week Low | 3.29 |
| Volume | 37,152 |
| Average Volume | 694,852 |
| Market Cap | 4.73M |
| PE | -19.56 |
| EPS | -0.18 |
| Moving Average 50 Days | 5.35 |
| Moving Average 200 Days | 17.54 |
| Change | 0.05 |
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
GlobeNewswire Inc.
Feb 17, 2026 1:44 PM GMT
CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage immuno-oncology company developing next-generation CD47-blockade therapies, today announced the pricing
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
GlobeNewswire Inc.
Oct 30, 2025 2:04 PM GMT
LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Underst
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
GlobeNewswire Inc.
Jul 28, 2025 11:30 AM GMT
Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic ValueLA PALMA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Liminatus